Brief: Basilea Gets Carb-X Grant Of Up To USD 2.7 Mln To Develop Novel-Class Antibiotic

Basilea Pharmaceutica AG, Allschwil

19/05/2021 06:19

May 19 (Reuters) - BASILEA PHARMACEUTICA AG  BSLN.S :
    * BASILEA AWARDED CARB-X GRANT OF UP TO USD 2.7 MILLION TO
DEVELOP
NOVEL-CLASS ANTIBIOTIC

Source text for Eikon:  ID:nGNE8l6Cj8 
Further company coverage:  BSLN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))